A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer

Inclusion Criteria: * Postmenopausal female between 18 and 70 years old * ECOG performance status of ≤ 1 * Life expectancy more than 3 months * Histologically confirmed metastatic breast cancer * ER and\&or PR pqositive, HER2-negative * Disease progression during adjuvant or first-line endocrine therapy, or endocrine naive but unsuitable for endocrine therapy alone * No pretreated chemotherapy for metastatic disease * Have at least one target lesion according to RECIST 1.1 * No therapy (chemotherapy, endocrine therapy, target therapy and operation) within 4 weeks before enrollment * Hemoglobin ≥ 90 g/L, Absolute Neutrophil Count ≥ 1.5×10\^9/L, Platelet Count ≥ 75×10\^9/L, Serum Bilirubin ≤ 1.5×ULN, ALT and AST ≤ 1.5×ULN, Serum Creatinine ≤ 1×ULN, Endogenous Creatinine Clearance\>50ml/min Exclusion Criteria: * Pregnant or lactating women * Evidence of CNS metastasis * Seriously uncontrolled infection * History of another malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix * Pretreated with Fulvestrant * Pretreated with two or more lines of endocrine therapy